New 15-Strain HPV vaccine trial aims to broaden cancer protection
NCT ID NCT06756269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new 15-valent HPV vaccine to see if it is safe and triggers a strong immune response. It involves 330 healthy Chinese volunteers aged 9 to 45. Participants will receive three doses of the vaccine or a placebo, and researchers will monitor side effects and measure antibody levels. The goal is to protect against more HPV types than current vaccines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
RECRUITINGNanning, Guangxi, 530028, China
Contact Phone: •••-•••-•••• Email: •••••@•••••